Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VEGF857
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravesical
01
Overview
VEGF857 is an antisense oligodeoxynucleotide (AS-ODN) designed to target and inhibit the expression of vascular endothelial growth factor (VEGF). By binding to VEGF mRNA, it prevents the translation of the protein, thereby inhibiting neo-angiogenesis and sensitizing tumor cells to chemotherapy. In preclinical studies involving human transitional bladder cancer cell lines (EJ28 and 5637), VEGF857 has demonstrated the ability to significantly enhance the cytotoxic effects of agents such as mitomycin C, gemcitabine, and cisplatin by promoting antisense-mediated apoptosis. It is primarily investigated as a potential additive approach to enhance the therapeutic benefit of intravesical instillation treatment schedules for bladder cancer.
- Other names
- VEGF antisense oligodeoxynucleotide 857anti-VEGF AS-ODN 857
02
Targets
Beyond the preview
Go deeper on VEGF857.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VEGF857.